Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-γ agonists through induction of apoptosis

被引:311
作者
Tsubouchi, Y
Sano, H
Kawahito, Y
Mukai, S
Yamada, R
Kohno, M
Inoue, K
Hla, T
Kondo, M
机构
[1] Kyoto Prefectural Univ Med, Dept Internal Med 1, Kamigyo Ku, Kyoto 6028566, Japan
[2] Univ Connecticut, Sch Med, Ctr Vasc Biol, Dept Physiol, Farmington, CT 06030 USA
关键词
D O I
10.1006/bbrc.2000.2436
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Peroxisome proliferator-activated receptors (PPARs), members of the nuclear hormone receptors superfamily, have an important regulatory role in adipogenesis and inflammation. PPAR-gamma Ligands induce terminal differentiation and growth inhibition of human breast cancer cells and prostatic cancer cells. In this study, we demonstrated that PPAR-gamma, but not PPAR-alpha, was expressed in human lung cancer cell lines by reverse transcription-polymerase chain reaction (RT-PCR) and Western blot analysis. We also found that the synthetic PPAR-gamma agonist thiazolidinedione compounds (troglitazone) and the endogenous PPAR-gamma hgand, 15-deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)), inhibited the growth of human lung cancer cells through the induction of apoptosis. However, PPAR-alpha agonist (bezafibrate) and other prostanoids (PGE(2), PGF(2 alpha)) did not induce apoptosis. These findings suggest that PPAR-gamma may play an important role in the pathogenesis of lung cancer and that PPAR-gamma agonist may be useful therapeutic agents in the treatment of human lung cancer. (C) 2000 Academic Press.
引用
收藏
页码:400 / 405
页数:6
相关论文
共 42 条
[1]   PPAR gamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A [J].
Altiok, S ;
Xu, M ;
Spiegelman, BM .
GENES & DEVELOPMENT, 1997, 11 (15) :1987-1998
[2]   Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans - No alteration in adipose tissue of obese and NIDDM patients [J].
Auboeuf, D ;
Rieusset, J ;
Fajas, L ;
Vallier, P ;
Frering, V ;
Riou, JP ;
Staels, P ;
Auwerx, J ;
Laville, M ;
Vidal, H .
DIABETES, 1997, 46 (08) :1319-1327
[3]   Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Δ12,14-prostaglandin J2 [J].
Bishop-Bailey, D ;
Hla, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (24) :17042-17048
[4]   Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance [J].
Boehm, T ;
Folkman, J ;
Browder, T ;
OReilly, MS .
NATURE, 1997, 390 (6658) :404-407
[5]   Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat [J].
Braissant, O ;
Foufelle, F ;
Scotto, C ;
Dauca, M ;
Wahli, W .
ENDOCRINOLOGY, 1996, 137 (01) :354-366
[6]   Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells [J].
Brockman, JA ;
Gupta, RA ;
DuBois, RN .
GASTROENTEROLOGY, 1998, 115 (05) :1049-1055
[7]  
CASTAIGNE S, 1990, BLOOD, V76, P1704
[8]   Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages [J].
Chinetti, G ;
Griglio, S ;
Antonucci, M ;
Torra, IP ;
Delerive, P ;
Majd, Z ;
Fruchart, JC ;
Chapman, J ;
Najib, J ;
Staels, B .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (40) :25573-25580
[9]   The PPAR alpha-leukotriene B-4 pathway to inflammation control [J].
Devchand, PR ;
Keller, H ;
Peters, JM ;
Vazquez, M ;
Gonzalez, FJ ;
Wahli, W .
NATURE, 1996, 384 (6604) :39-43
[10]   CONTROL OF THE PEROXISOMAL BETA-OXIDATION PATHWAY BY A NOVEL FAMILY OF NUCLEAR HORMONE RECEPTORS [J].
DREYER, C ;
KREY, G ;
KELLER, H ;
GIVEL, F ;
HELFTENBEIN, G ;
WAHLI, W .
CELL, 1992, 68 (05) :879-887